Caitlin Powell Gimpel
Biography
Overview
Caitlin Powell Gimpel is an associate and practices in the areas of Corporate M&A and Private Equity.
Caitlin advises American, Italian and multinational clients on complex business transactions, including domestic and international mergers and acquisitions, leveraged buyouts, corporate carve-out transactions, corporate recapitalizations and equity financings, executive compensation and incentive equity arrangements, and corporate governance matters. She has extensive experience in private equity, including in transactions focused on the software, technology, healthcare, industrial materials, payment processing, and food and consumer product industries.
Prior to joining White & Case, Caitlin practiced in the Chicago office of another international law firm.
Prior to practicing law, Caitlin worked for the Italian Trade & Investment Agency, a joint agency of the Italian Ministry of Foreign Affairs and the Italian Ministry of Economic Development.
Experience
- BC Partners LLP in connection with its co-controlling investment, together with US global private investment firm Bain Capital Private Equity, in Fedrigoni S.p.A.
- The Seller in connection with the sale of the entire share capital in Valeas S.p.A., a Milan based pharmaceutical company active in the Italian market.
- Piovan S.p.A., a global leader in the development and manufacturing of automation systems for the storage, conveying and processing of polymers, bio-resins, recycled plastic, food fluids, food and non-food powders, in connection with the acquisition of the entire share capital in Sewickley Capital, which owns 100 percent of IPEG, from the selling shareholders of Sewickley Capital for US$125 million.
- Kedrion S.p.A., an international pharmaceutical company engaged in developing and distributing plasma-derived medicinal products, in connection with its agreement to acquire Prometic Biotherapeutics Inc., a Canadian corporation and Prometic Bioproduction Inc., a US corporation and an option to acquire the remaining plasma-derived therapeutic business from NASDAQ listed company Liminal BioSciences Inc., together with approximately 100 employees.
- De'Longhi Industrial S.A., the Luxembourg-based home appliances company, in connection with the acquisition of an additional 33.34 percent stake in La Marzocco International, a Seattle-based espresso and coffee machine maker, increasing its stake to over 50 percent.
- IMA S.p.A., world leader in the design and manufacturing of automatic machines for the processing and packaging of pharmaceuticals, cosmetics, food, tea and coffee, in connection with its acquisition of Thomas Engineering LLC, a USA leading player in the tablet-coating equipment industry.
- Takeda in connection with an agreement to divest a portfolio of select non-core prescription pharmaceutical products sold in China to Hasten Biopharmaceutic Co. Ltd. for approximately US$322 million.
- International Game Technology Plc in connection with the agreement by its wholly-owned subsidiary Lottomatica Holding S.r.l. to sell 100 percent of the share capital of Lottomatica Videolot Rete S.p.A. and Lottomatica Scommesse S.r.l. to Gamenet Group S.p.A., a subsidiary of funds managed by an affiliate of Apollo Global Management, Inc. for €950 million.
- De'Longhi Group in connection with the acquisition of 100 percent of Capital Brands Holdings, LLC for expected consideration of US$420 million.
- BC Partners in connection with the M&A, financing, capital markets and regulatory aspects of BC Partners' acquisition of an up to approximately 45 percent stake in SOFIMA, the holding company that controls IMA S.p.A., for a total value of almost €2.1 billion.
- Datalogic USA, Inc., indirectly controlled by Datalogic S.p.A., an Italian company listed on the Italian Stock Exchange, in connection with the sale of 85 percent of its subsidiary Solution Net Systems Inc. to the US private equity fund Architect Equity.
- Takeda Pharmaceutical Company, a multinational pharmaceutical and biopharmaceutical company, in connection with its US$670 million sale of a portfolio of select non-core over-the-counter and prescription pharmaceutical products, as well as two manufacturing sites located in Denmark and Poland, to Orifarm Group, a Danish pharmaceutical company.
